Literature DB >> 2046690

Early indicators for carcinogenesis in sex-hormone-sensitive organs.

F Neumann1.   

Abstract

Hormones induce tumours in various target tissues in different species of laboratory animals in long-term toxicity studies. Examples of such tumours are: mammary gland tumours in beagle dogs after long-term treatment with progestogens or progestogen/oestrogen combinations; pituitary and mammary gland tumours in rats and mice after long-term treatment with oestrogens or progestogens with an oestrogenic partial effect; interstitial cell tumours in rats after chronic overstimulation by endogenous luteinising hormone; endometrial carcinomas in rats after chronic treatment with dopamine agonists. As a rule every hormone when given in excessive doses over prolonged periods can induce a tumour in the relevant target organs. Drugs or chemicals which stimulate or inhibit the endogenous hormone production of certain endocrine organs can have the same effect. Tumour induction can be a direct or indirect effect involving specific regulatory mechanisms. In general, the induction is preceded by excessive hyperplasia of the target tissue concerned or with regard to the pituitary where excess production of the stimulating hormone occurs. Tumour induction in chronic toxicity studies can usually be predicted by determining hormone levels in short-term studies. Hormones and drugs or chemicals which induce tumours when given in doses high enough to induce hyperplasia are unlikely to do so by a genotoxic mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046690     DOI: 10.1016/0027-5107(91)90067-x

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  8 in total

Review 1.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

2.  Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances.

Authors:  Benson T Akingbemi; Renshan Ge; Gary R Klinefelter; Barry R Zirkin; Matthew P Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-08       Impact factor: 11.205

Review 3.  Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis.

Authors:  S Nandi; R C Guzman; J Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

4.  Luteinizing hormone promotes gonadal tumorigenesis in inhibin-deficient mice.

Authors:  Ankur K Nagaraja; Julio E Agno; T Rajendra Kumar; Martin M Matzuk
Journal:  Mol Cell Endocrinol       Date:  2008-07-09       Impact factor: 4.102

5.  Transcriptomics analysis and hormonal changes of male and female neonatal rats treated chronically with a low dose of acrylamide in their drinking water.

Authors:  Reyna Cristina Collí-Dulá; Marvin A Friedman; Benjamin Hansen; Nancy D Denslow
Journal:  Toxicol Rep       Date:  2016-03-19

6.  Hyperglycemia contributes to the development of Leydig cell hyperplasia in male Spontaneously Diabetic Torii rats.

Authors:  Yoshitomi Nakane; Yusuke Kemmochi; Naoto Ogawa; Tomohiko Sasase; Takeshi Ohta; Yoshikazu Higami; Fumio Fukai
Journal:  J Toxicol Pathol       Date:  2020-03-20       Impact factor: 1.628

Review 7.  Revisiting the evidence for genotoxicity of acrylamide (AA), key to risk assessment of dietary AA exposure.

Authors:  Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-03       Impact factor: 5.153

8.  A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism.

Authors:  David A Brott; Håkan A S Andersson; Jane Stewart; Lorna Ewart; Greg Christoph; Johannes Harleman; Duncan Armstrong; Lewis B Kinter
Journal:  Toxicol Rep       Date:  2014-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.